Biogen is under investigation by Pomerantz LLP for possible securities fraud following the release of Phase 2 trial results for its Alzheimer's drug candidate diranersen. Although Biogen called the results "compelling," the trial failed to meet its primary dose-response endpoint, causing the stock to fall 6.43% on May 14, 2026. The investigation will examine whether Biogen and its executives engaged in unlawful business practices. This legal scrutiny could impact investor confidence and the company's future drug development efforts.
The Gross Law Firm has announced an investigation into possible securities fraud involving Biogen Inc. Investors who suffered losses on Biogen stock are encouraged to contact the firm to discuss their legal rights. The firm alleges that misleading st...
Biogen's stock struggles to surpass its $206 resistance level despite the company's acquisition of Apellis and strong sales growth of its Alzheimer's drug Leqembi, which saw a 75% year-over-year increase to $168 million in Q1 2026. However, skepticis...
